Evotec's Registration Statement in Connection with its Proposed
Acquisition of Renovis Declared Effective
Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange,
Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today
that the U.S. Securities and Exchange Commission (SEC) has declared
effective Evotec's Registration Statement on Form F-4, which is
required for the completion of the merger transaction with Renovis,
Inc., a South San Francisco based biopharmaceutical company focused
on the discovery and development of drugs for major medical needs in
the areas of neurological and inflammatory diseases. This is an
important milestone in connection with the proposed acquisition by
Evotec of all of the shares of Renovis as it is clearing the way for
Renovis to call a stockholders' meeting to vote on the acquisition.
Renovis has called a special stockholders' meeting for May 1, 2008
for that purpose.
The board of directors of Renovis and Evotec have approved the
transaction and the board of directors of Renovis has recommended
that its stockholders approve the transaction.
Contact:
Anne Hennecke, SVP, Investor Relations & Corporate Communications,
Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com
Forward looking statements
Information set forth in this report contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about the anticipated benefits of Evotec's products, the
timing of the completion of the transaction between Evotec and
Renovis, the anticipated benefits of the business combination
transaction involving Evotec and Renovis, including future financial
and operating results, the combined company's plans, objectives,
expectations and intentions, the anticipated timing and results of
the combined company's clinical and pre-clinical programs, and other
statements that are not historical facts. Evotec cautions readers
that any forward-looking information is not a guarantee of future
performance and that actual results could differ materially from
those contained in the forward-looking information. These include
risks and uncertainties relating to: the ability to obtain regulatory
approvals of the transaction on the proposed terms and schedule; the
parties' ability to complete the transaction because conditions to
the closing of the transaction may not be satisfied; the failure to
successfully integrate the businesses; unexpected costs or
liabilities resulting from the transaction; the risk that synergies
from the transaction may not be fully realized or may take longer to
realize than expected; disruption from the transaction making it more
difficult to maintain relationships with customers, employees or
suppliers; competition and its effect on pricing, spending,
third-party relationships and revenues; the need to develop new
products and adapt to significant technological change;
implementation of strategies for improving internal growth; use and
protection of intellectual property; general worldwide economic
conditions and related uncertainties; future legislative, regulatory,
or tax changes as well as other economic, business and/or competitive
factors; and the effect of exchange rate fluctuations on
international operations.
The risks included above are not exhaustive. The most recent reports
on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by
Renovis with the Securities and Exchange Commission contain
additional factors that could impact the combined company's
businesses and financial performance. The parties expressly disclaim
any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in the
parties' expectations or any change in events, conditions or
circumstances on which any such statement is based.
Additional information
Evotec has filed a Registration Statement on Form F-4 with the
Securities and Exchange Commission in connection with the proposed
merger. Evotec and Renovis expect to mail a joint proxy
statement/prospectus, which will form part of the Registration
Statement on Form F-4, to stockholders of Renovis in connection with
the proposed merger. This document will contain important information
about the merger and should be read before any decision is made with
respect to the merger. Investors and stockholders will be able to
obtain free copies of this document and any other documents filed or
furnished by Evotec or Renovis through the website maintained by the
Securities and Exchange Commission at www.sec.gov. Free copies of
these documents may also be obtained from Evotec, by directing a
request to Evotec's Investor Relations department at
Schnackenburgallee 114, 22525 Hamburg, Germany, or from Renovis, by
directing a request to Renovis' Investor Relations department at Two
Corporate Drive, South San Francisco, California 94080.
In addition to the documents referenced above, Renovis files or
furnishes annual, quarterly and current reports, proxy statements and
other information with the Securities and Exchange Commission. You
may read and copy any reports, statements or other information filed
or furnished by Renovis at the SEC's Public Reference Room at Station
Place, 100 F Street, N.E., Washington, D.C. 20549. You can request
copies of these documents by writing to the SEC and paying a fee for
the copying cost. Please call the SEC at 1-800-SEC-0330 for more
information about the operation of the Public Reference Room.
Renovis's SEC filings are also available to the public at the SEC's
web site at www.sec.gov, or at their web site at www.renovis.com.
--- End of Message ---
Evotec AG
Schnackenburgallee 114 Hamburg Germany
WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover;